- Recent Funding
- Investors
- RA Capital Management
RA Capital Management portfolio
RA Capital Management has 44 portfolio companies on record at Recent Funding, with 19 investments in the last 12 months.
About this page
It led 17 of the 56 rounds it joined. Its most recent investment on record is Delix's funding round in November 2026, alongside OMX Ventures, Vestal Point Capital, Dolby Family Ventures and 6 others. By category, its portfolio leans toward Health and bio (42) and Manufacturing and industrial (4). It has co-invested with Janus Henderson Investors, Soleus Capital and Sofinnova Partners, most often Janus Henderson Investors (11 rounds).
What RA Capital Management invests in
- Health and bio · 42 · 95%
- Manufacturing and industrial · 4 · 9%
- Developer tools and cloud · 3 · 7%
- Climate and energy · 2 · 5%
- Robotics and hardware · 2 · 5%
- Real estate and construction · 1 · 2%
- Education · 1 · 2%
- Consumer and social · 1 · 2%
RA Capital Management recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| round | OMX Ventures, Vestal Point Capital, Dolby Family Ventures +6 | ||
| Series A · $90M · lead | Cancer Research Horizons, University of Oxford, Oxford Science Enterprises +1 | ||
| Series B+ · $200M | Redmile Group, Janus Henderson Investors (lead), OrbiMed (lead) +6 | ||
| Series A · $32M | Atlas Innovate, Valo Ventures, VXI Capital (lead) | ||
| Series A · $103M · lead | 4BIO Capital, UPMC Enterprises, Deep Track Capital +4 | ||
| Series B+ · $66M | Redmile Group, NEA, Samsara Biocapital +6 | ||
| Series B+ · $188M | Milky Way Investments (lead), ARCH Venture Partners, Gates Frontier +2 | ||
| Series B+ · $75M | Milky Way Investments (lead), ARCH Venture Partners, LoLa Capital Partners +5 |
How RA Capital Management invests
RA Capital Management portfolio companies
DDelixround · Nov 2026
AAlethio Therapeutics$90MSeries A · Nov 2026
SStar Therapeutics$200MSeries B+ · Oct 2026
OOptivolt$32MSeries A · Oct 2026
EEstuary Biotherapeutics$103MSeries A · Oct 2026
AAbcuro$66MSeries B+ · Aug 2026
LLifeMine Therapeutics$188MSeries B+ · Aug 2026
CCelea Therapeutics$180MSeries A · Jul 2026
CContraline$92.5MSeries B+ · Jun 2026
CCellCentric$220MSeries B+ · May 2026
PPinnacle Medicines$89MSeries B+ · Mar 2026
AAtavistik Bio$40MSeries B+ · Mar 2026
NNexcure$19MSeries A · Mar 2026
AAngitia Bio$130MSeries B+ · Feb 2026
CCorxel$287MSeries B+ · Jan 2026KKinaset Therapeutics$103MSeries B+ · Jan 2026
AAmbros Therapeutics$125MSeries A · Dec 2025
TTriana Bio$120MSeries B+ · Dec 2025
SSidera Bio$109.99MSeries A · Nov 2025
RReframe Systems$20MSeries A · Aug 2025
VVerdiva Bio$410MSeries A · Jan 2025
AAlpha-9 Oncology$175MSeries B+ · Oct 2024
IIDRx$120MSeries B+ · Aug 2024
BBright Peak Therapeutics$90MSeries B+ · Jun 2024
AAltruBio$225MSeries B+ · May 2024
AAsher Bio$55MSeries B+ · Apr 2024
TTorl Bio$158MSeries B+ · Apr 2024
FFrontier Medicines$80MSeries B+ · Feb 2024
MMMI$110MSeries B+ · Feb 2024
CClaris Bio$57MSeries A · Jan 2024
AAiolos Bio$245MSeries A · Nov 2023
MMariana Oncology$175MSeries B+ · Sep 2023
CCurevo VaccineSeries A · Nov 2022
JJnana Therapeutics$107MSeries B+ · Nov 2022
AAnsa Biotechnologies$68MSeries A · Apr 2022
SSynthego$200MSeries B+ · Feb 2022
TTasso$100MSeries B+ · Dec 2021
TT-Knife$110MSeries B+ · Aug 2021
EElement Biosciences$276MSeries B+ · Jun 2021
SSynthekine$108MSeries B+ · Jun 2021
FForge Biologics$120MSeries B+ · Apr 2021
AAdcytherixbacker
WWindward Biobacker
EEnara Biobacker
| Company | Round with RA Capital Management | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
round | undisclosed | Nov 9, 2026 round |
Health and bio |
Series A · $90M · lead | $90M | Nov 5, 2026 Series A |
Health and bio |
Series B+ · $200M | $415M | Oct 23, 2026 Series B+ |
Climate and energy |
Series A · $32M | $40M | Oct 21, 2026 Series A |
Health and bio |
Series A · $103M · lead | $103M | Oct 16, 2026 Series A |
Health and bio |
Series B+ · $66M | $463M | Aug 18, 2026 Series B+ |
Health and bio |
Series B+ · $188M | $543M | Aug 6, 2026 Series B+ |
Health and bio |
Series A · $180M | $180M | Jul 2, 2026 Series A |
Health and bio |
Series B+ · $92.5M · lead | $105.45M | Jun 2, 2026 Series B+ |
Health and bio |
Series B+ · $220M | $340M | May 6, 2026 Series B+ |
Health and bio |
Series B+ · $89M | $89M | Mar 26, 2026 Series B+ |
Health and bio |
Series B+ · $40M · lead | $220M | Mar 5, 2026 Series B+ |
Health and bio |
Series A · $19M · lead | $19M | Mar 5, 2026 Series A |
Health and bio |
Series B+ · $130M | $130M | Feb 12, 2026 Series B+ |
Health and bio |
Series B+ · $287M | $287M | Jan 26, 2026 Series B+ |
Health and bio |
Series B+ · $103M · lead | $143M | Jan 9, 2026 Series B+ |
Health and bio |
Series A · $125M · lead | $125M | Dec 16, 2025 Series A |
Health and bio |
Series B+ · $120M | $120M | Dec 3, 2025 Series B+ |
Health and bio |
Series A · $109.99M | $109.99M | Nov 4, 2025 Series A |
Robotics and hardware |
Series A · $20M | $20M | Aug 26, 2025 Series A |
Health and bio |
Series A · $410M | $410M | Jan 9, 2025 Series A |
Health and bio |
Series B+ · $175M | $175M | Oct 23, 2024 Series B+ |
Health and bio |
Series B+ · $120M · lead | $242M | Aug 8, 2024 Series B+ |
Health and bio |
Series B+ · $90M | $125M | Aug 17, 2026 Series B+ |
Health and bio |
Series B+ · $225M | $288M | May 21, 2024 Series B+ |
Health and bio |
Series B+ · $55M · lead | $218M | Apr 16, 2024 Series B+ |
Health and bio |
Series B+ · $158M | $412M | Oct 7, 2025 Series B+ |
Health and bio |
Series B+ · $80M | $235.5M | Aug 28, 2025 Series B+ |
Health and bio |
Series B+ · $110M | $310M | Oct 8, 2026 Series B+ |
Health and bio |
Series A · $57M | $175M | Jul 28, 2026 Series B+ |
Health and bio |
Series A · $245M | $245M | Nov 20, 2023 Series A |
Health and bio |
Series B+ · $175M | $175M | Sep 7, 2023 Series B+ |
Health and bio |
Series A | undisclosed | Mar 18, 2025 Series B+ |
Health and bio |
Series B+ · $107M | $207M | Nov 15, 2022 Series B+ |
Health and bio |
Series A · $68M | $122.4M | Oct 1, 2025 Series B+ |
Health and bio |
Series B+ · $200M | $459M | Feb 17, 2022 Series B+ |
Health and bio |
Series B+ · $100M · lead | $123.1M | Dec 16, 2021 Series B+ |
Health and bio |
Series B+ · $110M | $188M | Aug 2, 2021 Series B+ |
Health and bio |
Series B+ · $276M | $823M | Jun 9, 2026 Series B+ |
Health and bio |
Series B+ · $108M | $290M | Jan 6, 2023 Series B+ |
Health and bio |
Series B+ · $120M · lead | $250M | Sep 12, 2022 Series B+ |
Health and bio |
backer | undisclosed | Oct 16, 2025 Series A |
Health and bio |
backer | $200M | May 5, 2026 round |
Health and bio |
backer | $32.5M | Jun 2, 2026 Series B+ |
Most frequent co-investors
JJanus Henderson Investors11 shared rounds · last Oct 23, 2026
SSoleus Capital7 shared rounds · last Oct 23, 2026
SSofinnova Partners6 shared rounds · last Nov 5, 2026
OOrbiMed6 shared rounds · last Oct 23, 2026
RRedmile Group6 shared rounds · last Oct 23, 2026
SSamsara Biocapital6 shared rounds · last Aug 18, 2026
IInvus6 shared rounds · last Aug 6, 2026
FForbion Capital Partners6 shared rounds · last May 6, 2026
LLogos Capital6 shared rounds · last Mar 26, 2026
WWellington Management6 shared rounds · last Feb 12, 2026
DDeerfield6 shared rounds · last Feb 23, 2024
NNew Leaf Venture Partners5 shared rounds · last Oct 23, 2026
Similar investors
BB Capital47 companies · 13 deals in 12 mo
FFidelity40 companies · 6 deals in 12 mo
SSignalFire39 companies · 10 deals in 12 mo
QQuiet Capital51 companies · 8 deals in 12 mo
GGlobal Brain Corporation52 companies · 8 deals in 12 mo
EEuropean Innovation Council Fund55 companies · 13 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 56 rounds on Recent Funding that name RA Capital Management. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists RA Capital Management, which is a subset of its real portfolio. API: /api/v1/investors/ra-capital-management (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy